At its June 12 meeting in Washington, the Cosmetic Ingredient Review Expert Panel questioned its role in assessing the safety of nano-sized cosmetic ingredients in light of FDA’s draft guidance on the topic.
Issued April 20, FDA’s draft guidance suggests that the cosmetics industry may need to modify premarket testing methods to account for nanomaterials’ unique characteristics and risks, compared with their macrosized...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?